Allogeneic transplantation of peripheral blood progenitor cells in children: Experience of two pediatric centers

R. Miniero, A. Busca, F. Bonetti, G. Giorgiani, M. Zecca, M. Berger, E. Incarbone, E. Vassallo, C. Perotti, F. Locatelli

Research output: Contribution to journalArticlepeer-review


Between February 1995 and August 1997, 11 children (eight males, three females) aged 4-16 years (median 7 years) underwent allogeneic PBPC transplantation for treatment of hematological disorders. Seven patients with acute leukemia (n = 5 ALL, n = 1 AML) or lymphoma (n = 1) received primary allogeneic PBPC transplantation, four patients received a second allotransplantation for graft failure (n = 1 AML, n = 1 sickle cell anemia) or disease recurrence (n = 1 ALL, n = 1 MDS). Five donors were HLA-identical siblings, five were 0-1 antigen mismatched family members and one was a matched unrelated donor. Donors received G-CSF 10-12 μg/kg/day for 3-7 days, and underwent one or two leukaphereses. The median cell yield per donor expressed per kg of recipient body weight was as follows: mononucleated cells 10.8 x 108/kg (range 4.7-21.2); CD34+ cells 8.6 x 106/kg (range 3.2-22); CD3+ cells 3.7 x 108/kg (range 2.7-7.5). All patients achieved an ANC > 0.5 x 109/l after a median of 12 days (11-18). An unsupported platelet count > 50 x 109/l was reached 15 days (13-21) after PBPC transplantation; four patients failed to reach this threshold. Acute GVHD (aGVHD) grades II to IV occurred in eight (73%) patients: seven of them experienced grade III-IV aGVHD. Seven patients evaluable for chronic GVHD (cGVHD) were scored as absent in five, limited in one and extensive in one patient. As of September 1997, six patients (55%) were alive between 60 and 938 days posttransplant (median follow-up 274 days); four patients with malignancy were alive in CR after primary allotransplantation, two patients were alive after a second PBPC transplant. Five patients have died with the main causes of death being aGVHD (n = 3), ARDS (n = 1), relapse of the underlying disease (n = 1). In conclusion, despite the limited number of patients, these preliminary results indicate that PBPC may be considered as an alternative to bone marrow for allografting also in children.

Original languageEnglish
JournalBone Marrow Transplantation
Issue numberSUPPL. 5
Publication statusPublished - 1997


  • Allogeneic transplantation in children
  • G-CSF priming
  • Peripheral blood progenitor cell

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Allogeneic transplantation of peripheral blood progenitor cells in children: Experience of two pediatric centers'. Together they form a unique fingerprint.

Cite this